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Sir,
There is growing interest in the role of secondary bacterial and
fungal infections as a cause of increased morbidity and mortality
in COVID-19 patients,1 with reports of up to 95% of COVID-19 inpa-
tients being prescribed antibiotics.2 Concerns have been raised
over the environmental implications of such a large-scale drug ad-
ministration3 and statements made about the potential impacts
of COVID-19-related antibiotic prescription on antimicrobial resist-
ance (AMR) and other toxicological effects on the environment.4
The UK National Strategy aims for a world in which AMR is
effectively contained, controlled and mitigated by 2040.5
Taking a ‘One Health’ approach to effective stewardship in set-
tings such as those being experienced in the current pandemic
will be key to minimizing the negative impacts of antibiotic use.
A large proportion of some drugs (and metabolites) are excreted
by patients into wastewater treatment works (WwTW), leading
to release of drug residues into effluent-receiving rivers and
coastal waters. Environmental concentrations and impacts will
be greatest where drugs are used in high volumes, pass through
WwTW largely undegraded and are discharged into rivers with
limited dilution.
Since 2006, the EMA has required risk assessments of
human medicines to allow standardized quantification of the
environmental impact of pharmaceuticals. Consequently, the
pharmaceutical industry has developed a database to provide
Predicted No Effect Concentrations as Minimum Inhibitory
Concentrations (PNEC-MIC) for active ingredients that may
select for AMR, or levels hazardous to fish and other environ-
mental species (PNEC-ENV).6 Combined with Predicted
Environmental Concentrations (PEC), generated using monitor-
ing and modelling data, a risk assessment may be carried out.
Should the PEC of individual drugs exceed either the PNEC-MIC
or PNEC-ENV, further investigations are required.
To examine the potential impact of antibiotic prescribing
in COVID-19 patients in the UK, we have undertaken a risk
assessment based on established principles.7 Patient numbers
were obtained for UK emergency hospitals set up temporarily
around the country to receive COVID-19 patients, with one chosen
for illustrative purposes, and details of WwTW capacity and river
water dilution serving the emergency hospital and associated
town were available from previous research.8 Antibiotic excre-
tion rates were obtained from the open literature. These data
allowed estimation of antibiotic loads entering the WwTW, over
and above the expected baseline (non-COVID-19) use for UK
patients.9 A freely available and validated wastewater process
model (SimpleTreat 4.0) was used to predict removal rates,
which allowed predictions of effluent concentrations for antibi-
otics of interest being discharged to surface waters. Based
on known dilution estimates, a PEC:PNEC ratio was derived to
provide a risk ratio.
We illustrate here data relevant to a single UK emergency
hospital (Harrogate, with 500 beds; see Figure S1, available as
Supplementary data at JAC Online) in different COVID-19
scenarios, providing environmental assessments relevant to
designing optimal drug use and waste management systems in a
One Health context. NICE COVID-19 guidance was followed, which
suggests that the first-line antibiotic should be doxycycline, with
amoxicillin as second line. NICE guidelines for secondary care
suggest doxycycline or a combination of clarithromycin and co-
amoxiclav. Clavulanic acid does not have a PNEC value, so data
presented here are for the impact of amoxicillin alone. Use of anti-
biotics in COVID-19 patients in hospitals will lead to the release of
drug residues into UK rivers or coastal waters from any WwTW
(Figure S1). Under pandemic scenarios, the use of antibiotics will
obviously increase dramatically, thus increasing the overall
burden on WwTW and potentially the receiving waters. Data
available for the UK make it possible to carry out a risk
assessment for site-specific areas.10 To examine more focused
regional impacts, we have calculated PEC data for the UK emer-
gency hospital at Harrogate (Figure 1) based on modelling tools
developed through the UK water industry-sponsored Chemical
Investigation Programme and briefly described above.7 We pre-
dict PEC:PNEC risk ratios of <1.0 for doxycycline and up to 5.70
for amoxicillin under two COVID-19 scenarios (all beds occupied
and 70% or 95% of patients prescribed antibiotics, with all
patients receiving either doxycycline or amoxicillin). The data
for amoxicillin indicate a potential environmental concern for
selection of AMR, but not toxicity to fish and other environmen-
tal organisms.
We have not modelled scenarios for hospitals where different
proportions of patients receive one or other antibiotic, though
in future this may inform best practice for minimizing selection
for AMR or causing toxic environmental effects.
We recommend more extensive environmental assessments
be undertaken for all antimicrobial medicines used during
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pandemics. This will facilitate development of a robust evidence
base in order to guide antibiotic prescribing choices that are less
likely to increase AMR11 and have the least environmental
impact, thus supporting the UK National Strategy.5 Such infor-
mation could also inform future decisions on the location of
emergency hospitals and wider drug and waste management
to ensure optimal patient and environmental outcomes during
pandemics.
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North of England Emergency Hospital case study Amoxicillin Doxycycline 
Baseline river PEC (µg/L) 0.03 0.003 
95% treated: river PEC (µg/L) 0.4 0.02 
PNEC-ENV (µg/L) 0.6 25.1 
PNEC-MIC (µg/L) 0.3 2.0 
Risk ratio assessment (PEC/PNEC-MIC) 
      Baseline PEC/PNEC-MIC 0.1 0.001 
      95% of hospital patients on antibiotics 1.7 0.010 
Risk ratio assessment (PEC/PNEC-ENV) 
      Baseline (pre-COVID-19 epidemic) 0.06 0.0001 
      95% of hospital patients on antibiotics 0.7 0.001 
Figure 1. Environmental risk assessments for amoxicillin and doxycycline for a worst-case COVID-19 scenario for patients in an emergency hospital
in Harrogate with risk ratios >1 highlighted in red. PNEC-MIC, Predicted No Effect Concentration, Minimum Inhibitory Concentration; PNEC-ENV,
Predicted No Effect Concentration, Environmental; PEC, Predicted Environmental Concentration. This figure appears in colour in the online version of
JAC and in black and white in the printed version of JAC.
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